VIVEVE MEDICAL INC (VIVE) Fundamental Analysis & Valuation

NASDAQ:VIVE • US92852W5013

0.2201 USD
-0.04 (-15.35%)
At close: Jan 18, 2023
0.2151 USD
0 (-2.27%)
After Hours: 1/18/2023, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VIVE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, VIVE scores 2 out of 10 in our fundamental rating. VIVE was compared to 184 industry peers in the Health Care Equipment & Supplies industry. While VIVE seems to be doing ok healthwise, there are quite some concerns on its profitability. VIVE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. VIVE Profitability Analysis

1.1 Basic Checks

  • In the past year VIVE has reported negative net income.
  • In the past year VIVE has reported a negative cash flow from operations.
VIVE Yearly Net Income VS EBIT VS OCF VS FCFVIVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

  • VIVE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VIVE Yearly ROA, ROE, ROICVIVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 1K -1K 2K 3K 4K

1.3 Margins

  • VIVE's Gross Margin of 16.39% is on the low side compared to the rest of the industry. VIVE is outperformed by 78.34% of its industry peers.
  • VIVE's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for VIVE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.5%
GM growth 5Y-22.91%
VIVE Yearly Profit, Operating, Gross MarginsVIVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. VIVE Health Analysis

2.1 Basic Checks

  • VIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VIVE has more shares outstanding
  • The debt/assets ratio for VIVE has been reduced compared to a year ago.
VIVE Yearly Shares OutstandingVIVE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
VIVE Yearly Total Debt VS Total AssetsVIVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

  • VIVE has an Altman-Z score of -34.95. This is a bad value and indicates that VIVE is not financially healthy and even has some risk of bankruptcy.
  • VIVE's Altman-Z score of -34.95 is on the low side compared to the rest of the industry. VIVE is outperformed by 94.47% of its industry peers.
  • VIVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.95
ROIC/WACCN/A
WACC8.03%
VIVE Yearly LT Debt VS Equity VS FCFVIVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 20M -20M -40M

2.3 Liquidity

  • A Current Ratio of 0.89 indicates that VIVE may have some problems paying its short term obligations.
  • VIVE has a Current ratio of 0.89. This is amonst the worse of the industry: VIVE underperforms 94.47% of its industry peers.
  • VIVE has a Quick Ratio of 0.89. This is a bad value and indicates that VIVE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • VIVE has a worse Quick ratio (0.74) than 88.94% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.74
VIVE Yearly Current Assets VS Current LiabilitesVIVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. VIVE Growth Analysis

3.1 Past

  • VIVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.74%, which is quite impressive.
  • The Revenue has been growing slightly by 2.34% in the past year.
  • Measured over the past years, VIVE shows a decrease in Revenue. The Revenue has been decreasing by -2.09% on average per year.
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.94%
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y-2.09%
Sales Q2Q%4.21%

3.2 Future

  • VIVE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.12% yearly.
  • Based on estimates for the next years, VIVE will show a very strong growth in Revenue. The Revenue will grow by 50.55% on average per year.
EPS Next Y7.44%
EPS Next 2Y19.13%
EPS Next 3Y18.12%
EPS Next 5YN/A
Revenue Next Year7.41%
Revenue Next 2Y31.78%
Revenue Next 3Y50.55%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIVE Yearly Revenue VS EstimatesVIVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
VIVE Yearly EPS VS EstimatesVIVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

Find the best growth stocksShow best growing peers

0

4. VIVE Valuation Analysis

4.1 Price/Earnings Ratio

  • VIVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VIVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VIVE Price Earnings VS Forward Price EarningsVIVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVE Per share dataVIVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • VIVE's earnings are expected to grow with 18.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.13%
EPS Next 3Y18.12%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VIVE Dividend Analysis

5.1 Amount

  • VIVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

VIVE Fundamentals: All Metrics, Ratios and Statistics

VIVEVE MEDICAL INC

NASDAQ:VIVE (1/18/2023, 8:00:02 PM)

After market: 0.2151 0 (-2.27%)

0.2201

-0.04 (-15.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10
Earnings (Next)03-15
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners2.98%
Ins Owner Change0%
Market Cap2.36M
Revenue(TTM)6.83M
Net Income(TTM)-28.14M
Analysts85
Price Target4.77 (2067.2%)
Short Float %0.04%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.16%
Min EPS beat(2)1.96%
Max EPS beat(2)12.36%
EPS beat(4)3
Avg EPS beat(4)-0.41%
Min EPS beat(4)-18.64%
Max EPS beat(4)12.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-3.16%
Max Revenue beat(2)0%
Revenue beat(4)0
Avg Revenue beat(4)-3.09%
Min Revenue beat(4)-7.29%
Max Revenue beat(4)0%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.34%
EPS NY rev (1m)0%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.83%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)-2.65
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.64
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.5%
GM growth 5Y-22.91%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.74
Altman-Z -34.95
F-Score4
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)64.33%
Cap/Depr(5y)133.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.94%
EPS Next Y7.44%
EPS Next 2Y19.13%
EPS Next 3Y18.12%
EPS Next 5YN/A
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y-2.09%
Sales Q2Q%4.21%
Revenue Next Year7.41%
Revenue Next 2Y31.78%
Revenue Next 3Y50.55%
Revenue Next 5YN/A
EBIT growth 1Y-6.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.4%
OCF growth 3YN/A
OCF growth 5YN/A

VIVEVE MEDICAL INC / VIVE FAQ

What is the ChartMill fundamental rating of VIVEVE MEDICAL INC (VIVE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VIVE.


Can you provide the valuation status for VIVEVE MEDICAL INC?

ChartMill assigns a valuation rating of 2 / 10 to VIVEVE MEDICAL INC (VIVE). This can be considered as Overvalued.


Can you provide the profitability details for VIVEVE MEDICAL INC?

VIVEVE MEDICAL INC (VIVE) has a profitability rating of 1 / 10.


What is the expected EPS growth for VIVEVE MEDICAL INC (VIVE) stock?

The Earnings per Share (EPS) of VIVEVE MEDICAL INC (VIVE) is expected to grow by 7.44% in the next year.